Of the pharmacological methods available, low dose heparin is the most widely used and thoroughly evaluated. The heparin is given subcutaneously in a dose'of 5000 units at 8 or 12 hourly intervals starting before the operation and continuing until the patient is ambuilant. A large multicentre trial showed significant reductions in the incidence of deep vein thrombosis and pulmonary embolism when patients receiving this regimen were compared with a control group receiving no prophylaxis. The only complication is wound haematoma, and this makes the'method unacceptable for neurosurgical operations and operations in which a lot of dissection is necessary. Results have also been disappointing in the high risk group of patients having hip prostheses inserted. Dihydroergotamine causes venous vasoconstriction thus increasing blood flow, and trials have shown that this may be useful when combined with heparin given subcutaneously. Side effects are rare but skin gangrene has been reported, and the drug should be avoided in patients with myocardial infarction, vasospastic disorders, peripheral arterial disease, or sustained hypotension.
Dextran is also effective. Its use does, however, require the intravenous infusion of 500-1000 ml of fluid before and on at least alternate days after operation. This is cumbersome and may interfere with fluid balance; furthermore, complications associated with bleeding are common.
In summary, a prophylactic regimen for a particular patient should be adopted after balancing the degree of risk against the potential' complications ofthe prophylaxis. All patients at risk should wear graduated compression stockings and heparin should be given subcutaneously to patients at particularly high risk.
Presentation and diagnosis Scanning the uptake of fibrinogen labelled with iodine-125 is a sensitive test, especially for early thrombosis confined to the calf, and permits serial analysis on consecutive days. Preparation for the test includes blocking the uptake of iodine by the thyroid, however, which makes the test suitable only for screening.
Pulmonary embolism
Pulmonary embolic disease also presents in various ways depending on the extent and age of the embolism. It can be classified as "massive" (more than half of the pulmonary arterial tree is occluded) or "minor," and as "acute" (of less than 48 hours' duration), "subacute," or "chronic." Acute massive embolism results in sudden reduction in cardiac output and circulatory collapse. Patients with subacute massive embolism and chronic thromboembolic disease-are rare and present with increasing dyspnoea, pulmonary hypertension, and right heart failure.
Acute minor embolism is most commonly seen, and may warn of an impending fatal embolus.
Minor chest radiograph may show pulmonary opacities, elevation of the diaphragm, effusion, atelectasis, and-in larger emboli-areas of oligaemia. Perfusion lung scans show deficits where the artery is obstructed, but in patients with coexistent respiratory disease simultaneous ventilation and perfusion scars are essential to see if there is normal ventilation in the areas of oligaemia. The SI Q3 T3 electrocardiographic pattern is pathognomonic of a large pulmonary embolus and reflects right heart strain, but it is present in less than half of patients with large emboli. Changes in blood gas tensions are non-specific but may offer a guide to the extent of the embolism. Pulmonary arteriography is the definitive investigation, but is indicated only in critically ill patients to confirm the diagnosis so that the correct treatment may be started.
The three main aims of treatment of deep vein thrombosis are to prevent extension of the thrombus, to reduce the risk of embolism, and to avoid the long term complications of the postphlebitic limb. The treatment will depend on the site and extent of the thrombus, which should be confirmed objectively. In about 80% ofcases the thrombus is confined to the calf veins, but it may propagate into the veins of the popliteal fossa, thigh, and pelvis. In some cases the thrombus arises in the iliofemoral segment, and may extend distally.
If the thrombi are small and confined to the calf treatment should be conservative and comprise limb exercise in bed, raising the foot of the bed, and wearing elastic compression stockings. For more-extensive thrombi the patient should be given heparin intravenously to maintain the activated partial thromboplastin time at 2-3 times the normal value. Recent studies, however, have suggested that calcium heparin given subcutaneously may be equally effective in preventing propagation of thrombi. Oral anticoagulant drugs should be started at the same time and continued for 8-12 weeks.
Warfarin is given in a loading dose of 20-30 mg and then daily, the dose being adjusted to maintain a prothrombin time of 1-7-3-0 times the normal value by using international reference thromboplastin.
Thrombolytic treatment with streptokinase or urokinase should be reserved for more extensive thrombosis. It is most effective when the thrombus is reasonably fresh and only partially occlusive, and may salvage deep veins-thus reducing the incidence of postphlebitic changes. BMJ VOLUME 303
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